5-Amino-1MQ: NNMT Inhibitor Research

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and epigenetic regulation. While not a peptide, 5-Amino-1MQ is frequently studied alongside peptide-based metabolic research compounds due to its complementary mechanism of action.

5-Amino-1MQ has a molecular weight of approximately 173.21 Da. It is a membrane-permeable, cell-active compound that inhibits NNMT with high potency (IC50 in the low micromolar range). The compound was developed through structure-activity relationship studies aimed at creating selective, bioavailable NNMT inhibitors for metabolic research.

NNMT has emerged as a target of significant interest in adipose tissue biology, energy metabolism, and epigenetic regulation. Its inhibition by 5-Amino-1MQ provides researchers with a pharmacological tool to study NNMT function in cellular and animal models.

Understanding why NNMT inhibition is of research interest requires context on the enzyme's role in metabolism.

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). This reaction sits at a metabolic crossroads affecting two critical pathways:

**NAD+ salvage pathway:** Nicotinamide is a precursor for NAD+ biosynthesis via the salvage pathway (nicotinamide → NMN → NAD+). By methylating nicotinamide into 1-MNA, NNMT diverts substrate away from NAD+ production. High NNMT activity therefore reduces NAD+ availability, which is relevant to research on cellular energy metabolism and aging.

**Methylation capacity:** The SAM-to-SAH conversion by NNMT consumes methyl groups, reducing the cell's methylation potential. SAM is the universal methyl donor for DNA methylation, histone methylation, and other epigenetic modifications. By consuming SAM, NNMT activity can influence the epigenetic landscape of the cell.

NNMT is highly expressed in white adipose tissue, and its expression is elevated in adipose tissue from obese rodent models and in human visceral fat. This tissue-specific expression pattern, combined with its metabolic positioning, has made NNMT a target for studying adipose tissue biology and energy balance.

5-Amino-1MQ inhibits NNMT by competing with nicotinamide for the enzyme's active site. The quinolinium scaffold mimics the pyridine ring of nicotinamide, while the amino substitution provides additional binding interactions that confer selectivity and potency.

The downstream consequences of NNMT inhibition in preclinical models include:

**Increased intracellular NAD+:** By blocking nicotinamide methylation, more nicotinamide remains available for the NAD+ salvage pathway. Studies in adipocyte cell lines show increased NAD+ levels following 5-Amino-1MQ treatment, measured by enzymatic cycling assays.

**Enhanced SAM/SAH ratio:** Reduced NNMT activity preserves SAM levels, increasing the cell's methylation potential. This shifts the epigenetic balance toward a more methylated state, which in adipocytes is associated with reduced expression of adipogenic genes.

**Metabolic reprogramming in adipocytes:** In 3T3-L1 adipocyte models, NNMT inhibition by 5-Amino-1MQ reduces lipid accumulation, decreases expression of adipogenic transcription factors (PPAR-gamma, C/EBP-alpha), and increases expression of genes associated with energy expenditure. Treated adipocytes show a phenotypic shift toward a more metabolically active state.

**AMPK pathway engagement:** Some studies report that NNMT inhibition activates AMPK signaling, potentially through increased NAD+ availability and its effects on SIRT1 and downstream metabolic regulators.

The primary preclinical data on 5-Amino-1MQ comes from adipocyte cell culture studies and diet-induced obesity rodent models.

Practical considerations for working with 5-Amino-1MQ in the laboratory:

**Solubility:** 5-Amino-1MQ is water-soluble and can be dissolved directly in aqueous buffers or cell culture media. It is also soluble in DMSO for concentrated stock solutions. If using DMSO, ensure the final DMSO concentration in cell culture does not exceed 0.1% to avoid solvent toxicity.

**In-vitro concentrations:** Published studies use 10-100 micromolar for adipocyte differentiation assays (7-14 day protocols) and 1-50 micromolar for acute NAD+ measurement assays (24-48 hours). Include a dose-response curve in initial experiments, as effective concentrations vary by cell type and endpoint.

**In-vivo administration:** Rodent studies have used oral gavage and intraperitoneal injection at concentrations of 10-30 mg/kg/day. The compound's water solubility facilitates oral administration, which is preferred for chronic metabolic studies.

**Key assays:** NNMT enzymatic activity (SAM consumption assay), NAD+ levels (enzymatic cycling), gene expression (RT-qPCR for PPAR-gamma, UCP1, PGC-1alpha), and lipid accumulation (Oil Red O) are the core readouts for characterizing 5-Amino-1MQ activity.

**Storage:** Store lyophilized material at -20°C. Reconstituted aqueous solutions are stable at 2-8°C for up to 7 days. DMSO stocks are stable at -20°C for several months.

*All materials are for research use only.*